Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"An interesting post "
Why do you think its interesting? I doubt any of us are interested in his bashing because your in a pissing contest with him.
More of those $13 + trades in pre-market. Looks like we'll be saying good bye to the $12's soon.
Spartex, I don't understand why your concerned about endo thickening if the expert in this area is pretty confident in the clinical plan. Did you read Dewophiles message 45929 on the biotech board?
I don't have any doubt that the data will be positive. Low risk and high rewards is a good combination. Phase IIb data for co-factor and Thiovir's development will be key drivers for a higher share price in the near future.
In order to have an abstract accepted for ASCO you need the information several months in advance. Culley, told me a long time ago that they did not anticipate having the trial completed in time. The company has also stated that they anticipate top line data in the third qtr. which further indicates that they will not be at ASCO. Some of us have estimated that the trial will be completed in June and results released in July. Maybe Levine can give us a better idea next week during the CC.
Mets, ANX will not be presenting at ASCO. They couldn't get the abstract prepared in time for presentation.
Yes, we are. I thought we said goodbye to the $11's last week, but I'm officially doing it today.
I read something about the new birth control pills are going to eliminate periods. Is there any difference in the mechanisms by which Proellex and birth control pills cause the cessation of periods. If there is no difference then it seems like this would not be a big concern.
5% drop on 50K shares. I know we have a small float, but sometimes the drops are to funny. I couldn't resist, bought a few more K.
Nothing is on the bid or ask for anything significant. Probably stay in this trading range today.
I would find it more interesting if he had participated in the most recent financing. Icahn has the option for another 10 million shares in the $2.20 range so he's just waiting to see how all the trial results come out before making a bigger investment. He got a sweet heart deal on the original financing, but ANX was able to use his name.
Trading over $12.00. I would love to see another EOD run like friday to make the traders buy higher.
I was never married to this stock and I didn't realize that Cornell was involved when I made my original investment. I've never been able to figure out how much upside would occur with positive data and I didn't like the wording in the press release. Probably reading to much into it.
Like I said, Good Luck
Sold this morning. Good luck guys.
Yes , they want to be compensated when ANX is bought out. ANX does not need to raise capital at this time.
I have no idea. If I had to guess then they may be doing some data mining which is not a positive. I hope that guy didn't work all weekend on such a poorly worded PR.
Your glad to be watching from the sidelines, but happy to give your two cents and say I think your screwed. We don't need any comments from the peanut gallery.
Megadoses of B12. The interesting thing is that B12 lozenges are already on the market. No one has gained FDA approval to market B12 for allergy indications, but a smart allergy sufferer may already have stumbled onto this theory.
I've been in ANX for over 4 yrs. Rode it up from $1, sold the highs and I've re-loaded down low. The only rumor which I'm hoping for is the RBC upgrade that was posted. ANX has a history of giving away the gains so don't rush buying more shares.
You may want to start putting a few dollars in MCU if you haven't done so. Thinly traded so set your buys low. Should double before you ever have to worry about positive clinical results.
"Legend in my own mind", You have no idea about the fun that Mets06 and some other posters have had on the ANX yahoo board over the years.
Phase IIb results are only a few months away if that long. Most bio-tech investors have no idea what the heck "co-factor" is and how big a market opportunity it could eventually be. We have a better then average chance of statistically positive results and then things could get interesting.
I don't know about you guys, but the hint of positive news on monday has got me pretty excited. I really think that no matter where it trades on monday it will end the week at the high so I'm not selling a share. I would love to see 10 million shares trade.
Huh? I couldn't find any upgrade, but it would explain todays trading.
Posted on the Yahoo board that RBC just initiated as a buy- $5 near term target $8+ - 12 month. Has anyone else seen a report?
I'll never understand why I don't have any GNVC. Nice chart. I doubt either one of the stocks you mention are included in any biotech index and the biotech composite is trading down so I'd discount program trading has caused todays rise.
I'm fully loaded and love the trading. Stock rose almost 50 cents and no one wanted to give up their shares. If you try to trade the stock you may be buying higher. Hope it continues since a few of my other bio's are taking a breather today.
If Podolski can't get 300 million for Androxal then hopefully they will continue the development instead of taking a low ball offer.. I don't know what the big rush is for selling Androxal anyway and hopefully he's not going to regret his promises about making a deal.
I've got a small position in Cobalis. I scan the board for any new developments. Phase II data looked good and the Phase III trial is constructed for the best chance of achieving positive results, but allergy trials are difficult to predict since its based on opinion of the participants.
I would take a bigger position position if I had any idea how high the price would move on positive results. It could be $1.50 or $4, whats the risk vs reward. We're all just guessing.
As far as ANX. Best thing is probably just to wait for Phase IIb results in a few months. I don't think it will get a big spike upward on any positive data, shorts will hold it down, but it would be a good buy at any price less then $5.
Good Luck,
The companies that do this work get back logged like any other company. I'm sure they gave CLSC an estimate, but there are any number of reasons why delays occur. They will probably announce Phase III results this month, but there's no reason to panic if it takes longer.
"delay in the release past April should not indicate any problems"
The company has stated that clinical data would be available this month. That was probably a mistake since they don't have any control over how long it will really take to compile the data. So a delay does not indicate any problems.
"Not exactly 100% sure but once the data is locked its kept away from any fraudulent activities"
The way it works is that the trial data from each study site is sent to an independent company for statistical analysis. The final analysis is given to the company at which time they review the findings prior to any release to the general public. If the data is good then it will be quickly disseminated, but a delay in the release past April should not indicate any problems.
I think this topic was discussed in detail during the January 07 presentation. May try listening to the Q&A period.
Somebody sold 10,900 shares in after hours @$11.10. I guess they got a margin call since that trade cost them about $6,000. The stock closed @ $11.95 in after hours.
It looks like someone moves the stock upward in after hours and pre-market to get buyers to chase it and then they dump their shares. The stock drifts up & down during the day which allows them to pick up their shares on the cheap for the next days trade. I may have to join the game.
One day the news services will pick up on "co-factors" potential revenues and Icahn's involvement then the stock will explode.
We're trading in a tight range, but the trend is up. I saw the 15K share sell this morning with little movement, but I think it caused a little sell-off afterwards.
I like the trading action in RPRX. Showing nice strength with minimal manipulation for such a thinly traded stock. Just waiting for the next leg up.
I attribute most of the price movement in RPRX to a few day traders. I never buy-in to the MM manipulation theories.
I didn't realize what an obnoxious ID that is. I should have never canceled it.
Icahn has made a few nice moves in the bio-tech sector lately. I'm wondering if a few folks are following him over to ANX. 7 million shorts are about to get Squeeeeeeeeeeeeeeeeezed.
What happened to this board? Did ANX ask that the information be removed or something? I also see that "06Mets" has been removed as co-moderator.
ALTU - The recently announced financing and the news of Eurands successful Phase III trial for pancreatic enzyme replacement therapy should place pressure on the stock price.
"Company’s Pancreatic Enzyme Replacement Therapy Significantly Improved Absorption of Fat and Protein during Clinical Trials
Milan, Italy; Dayton, Ohio -- April 4, 2007 - Eurand, a global specialty pharmaceutical company, today unveiled data from two phase III clinical trials on its lead product candidate, ZentaseTM, formerly EUR-1008, for the treatment of Exocrine Pancreatic Insufficiency (EPI). The US Food and Drug Administration (FDA) granted fast track status for Zentase for the treatment of EPI. The company intends to file for FDA approval during the second quarter of 2007 for this potentially first-in-class pancreatic enzyme replacement therapy."
http://www.eurand.com/News--events/News2...
CIBC: I had the opportunity to listen to Podolski's presentation today. I don't know if I've ever heard another CEO speak with his level of confidence. If he can stick with his timelines for the pipeline & partnerships then this will turn out to be a rewarding investment sooner rather then later.
Do you guys know how many people will be in the Thiovir clinical trial? Thiovir has more potential then the rest of the pipeline for getting the attention of the investing community. It could also lead to a nice partnership opportunity.